<DOC>
	<DOCNO>NCT02505893</DOCNO>
	<brief_summary>This prospective phase 2 , single-arm , mono-center pilot study . It design investigate whether give combination therapy consist minimal islet transplantation ( 1500 EIQ/Kg body weight ) , Thymoglobulin® ( ATG ) , Rapamune® ( rapamycin ) Neulasta® ( pegfilgastrim ) patient Type 1 Diabetes ( T1D ) onset safe secondarily , preserve insulin production . It involve 6 patient new-onset T1D . Each patient involve study screen period post-islet transplantation study period 52±2 week , include 1 treatment cycle 12 week , assessment treatment 5 follow-up visit schedule week 2±1 ( 14 day ) , 4±1 ( month 1 ) , 12±2 ( month 3 ) , 26±2 ( month 6 ) 52±2 ( month 12 ) .</brief_summary>
	<brief_title>Minimal Islet Transplant Diabetes Onset</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Ability provide write informed consent Mentally stable able comply protocol procedure duration study , include schedule followup visit examination Newonset T1D ( diagnosis diabetes within 180 day prior enrolment ) . Documentation diagnosis T1DM ( insulin deficiency ) , include date diagnosis , must obtain diagnose physician . Residual betacell function ( fast Cpeptide &gt; 0.3 ng/mLwhen plasma glucose level &gt; 70 mg/dL ≤ 200 mg/dL . Positive least one follow autoantibody typically associate T1DM : antibody glutamic acid decarboxylase ( antiGAD ) antibody protein tyrosine phosphataselike protein ( antiIA2 ) , zinc transporter autoantibody ; insulin autoantibody ( IAA ) . Please note : A subject positive IAA negative autoantibody eligible subject use insulin total ≥7 day . Currently require insulin T1DM treatment , require insulin therapy ( least 7 day ) diabetes time date diagnosis first dose study drug . Note : subject currently take twice daily commercially available premixed insulin eligible . MinimalHLA I A B mismatch least one HLA DR match Body mass index ( BMI ) ≥ 32.0 kg/m2 patient weight ≤50kg Insulin requirement &gt; 1.0 IU/kg/day HbA1c &gt; 10 % Blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg . Chronic disease apart diabetes , include type 2 diabetes Moderate severe renal impairment per calculate creatinine clearance ( CLcr ) &lt; 90 mL/min accord CockcroftGault formula ( CockcroftGault , 1976 ) Presence history macroalbuminuria ( &gt; 300mg/g creatinine ) . Hepatic dysfunction define increase ALT/AST upper limit normal ( ULN ) increase total bilirubin &gt; 3 mg/dL [ &gt; 51.3 μmol/L ] Pregnant breast feed woman . Unwillingness use effective contraceptive measure 4 month end study drug administration ( female male ) Active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) determine positive skin test clinical presentation , treatment suspect TB . Positive test acceptable associate history previous vaccination absence sign active infection . Positive test otherwise acceptable , even absence active infection time evaluation . Negative screen EpsteinBarr Virus ( EBV ) IgG determination Invasive aspergillus , histoplasmosis , coccidioidomycosis infection within one year prior study enrollment Any history malignancy except completely resect squamous basal cell carcinoma skin Known active alcohol substance abuse Baseline Hb low limit normal local laboratory ; lymphopenia ( &lt; 1,000/µL ) , neutropenia ( &lt; 1,500/µL ) , thrombocytopenia ( platelet &lt; 100,000/µL ) . Participants lymphopenia allow investigator determine additional risk obtains clearance hematologist A history Factor V deficiency Any coagulopathy medical condition require longterm anticoagulant therapy ( e.g. , warfarin ) transplantation ( lowdose aspirin treatment allow ) patient international normalized ratio ( INR ) &gt; 1.5 Severe coexist cardiac disease , characterize one condition : ) recent myocardial infarction ( within past 6 month ) b ) evidence ischemia functional cardiac exam within last year c ) leave ventricular ejection fraction &lt; 30 % . Symptomatic cholecystolithiasis . Acute chronic pancreatitis . Symptomatic peptic ulcer disease . Severe unremitting diarrhea , vomit gastrointestinal disorder potentially interfere ability absorb oral medication Hyperlipidemia despite medical therapy ( fast lowdensity lipoprotein [ LDL ] cholesterol &gt; 130 mg/dL , treat untreated ; and/or fast triglyceride &gt; 200 mg/dL ) Receiving treatment medical condition require chronic use systemic steroid , except use ≥ 5 mg prednisone daily , equivalent dose hydrocortisone , physiological replacement . Treatment antidiabetic medication insulin within 4 week enrollment Use investigational agent within 4 week enrollment . Administration live attenuate vaccine ( ) within 2 month enrollment . Any medical condition , opinion investigator , interfere safe participation trial . Treatment immunosuppressive regimen time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>